Modeling The Economic Burden Of Adult Vaccine-Preventable Diseases In The United States by Ozawa, Sachiko et al.
By Sachiko Ozawa, Allison Portnoy, Hiwote Getaneh, Samantha Clark, Maria Knoll, David Bishai,
H. Keri Yang, and Pallavi D. Patwardhan
Modeling The Economic Burden Of
Adult Vaccine-Preventable
Diseases In The United States
ABSTRACT Vaccines save thousands of lives in the United States every year,
but many adults remain unvaccinated. Low rates of vaccine uptake lead to
costs to individuals and society in terms of deaths and disabilities, which
are avoidable, and they create economic losses from doctor visits,
hospitalizations, and lost income. To identify the magnitude of this
problem, we calculated the current economic burden that is attributable
to vaccine-preventable diseases among US adults. We estimated the total
remaining economic burden at approximately $9 billion (plausibility
range: $4.7–$15.2 billion) in a single year, 2015, from vaccine-preventable
diseases related to ten vaccines recommended for adults ages nineteen
and older. Unvaccinated individuals are responsible for almost
80 percent, or $7.1 billion, of the financial burden. These results not only
indicate the potential economic benefit of increasing adult immunization
uptake but also highlight the value of vaccines. Policies should focus on
minimizing the negative externalities or spillover effects from the choice
not to be vaccinated, while preserving patient autonomy.
V
accines are one of the safest and
most cost-effective health interven-
tions, with numerous social and
economic benefits.1 Despite these
positive characteristics, adults in
the United States are not receiving vaccinations
at recommended levels. Forexample, theCenters
for Disease Control and Prevention (CDC) esti-
mates that approximately 42 percent of adults
ages eighteen and older received the influenza
vaccine in the 2015–16 flu season.2 Low vaccine
uptakemeans that preventable diseases result in
costs to individuals and society in terms of
deaths, disabilities, and economic losses from
doctor visits, hospitalizations, and lost income.
The positive health impacts of vaccination, in-
cluding reduced mortality and morbidity, are
recognized more often than the economic bur-
den from people not getting vaccinated. This
burden includes unexpected increases in health
expenditures and lost income as a result of re-
duced functional capacity. Estimating and con-
sidering the economic burden of adult vaccine-
preventable diseases is necessary for public
health spending decisions and for increasing
adult uptake of vaccines in the United States.
This project was designed to estimate the eco-
nomic burden that was attributable to vaccine-
preventable diseases in adults ages nineteen and
older in theUnitedStates for a single year. This is
a more comprehensive review of the economic
burden of vaccine-preventable diseases among
US adults than has previously been done, as
the focus to date has beenononeor a few specific
vaccine-preventable diseases.1,3–6 Our approach
was to estimate an age-stratified cross-section
of frequency and associated economic burden
of vaccine-preventable diseases among adults
at a specific point in time: 2015, the year of
the analysis. This approach can help inform fu-
ture national immunization program planning
and the allocation of health resources.
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Study Data And Methods
Scope Of Analysis This analysis focused on es-
timating the annual economic burden of dis-
eases associatedwith ten vaccines,which protect
against fourteen different pathogens, recom-
mended by the CDC for adults. The ten vaccines
protect against hepatitis A; hepatitis B; herpes
zoster (shingles); humanpapillomavirus (HPV);
influenza;measles,mumps, and rubella (MMR);
meningococcal disease; pneumococcal disease;
tetanus, diphtheria, and pertussis (Tdap/Td);
and varicella (chicken pox). A full list of these
vaccines, the pathogens, and the diseases they
cover is available in online Appendix A.7
Epidemiological Methodology Epidemio-
logical parameters, which are the variables that
describe the percentage of population immu-
nized, the vaccine efficacy rate, and several other
boundary-defining variables mentioned below,
were collected from a review of the CDC and
peer-reviewed literature to develop an Excel-
based cost-of-illness model. An extended bibli-
ography with the sources for these parameters is
included in Appendix B.7 Key epidemiological
variables included population data by age from
the 2010 census, immunization uptake, vaccine
efficacy, incidence rate, care seeking, and hospi-
talization rate. To fully account for potential
costs averted through increased adult vaccina-
tion, incidence rates were derived for unvacci-
nated and vaccinated individuals based on the
level of immunization uptake. These incidence
rates were applied to susceptible populations in
each cohort to estimate the annual number of
cases and subsequently assess the number of
people who received inpatient and outpatient
care. An illustrative decision tree appears in Ap-
pendix C.7
While the majority of pathogens prevented by
vaccines cause acute infections, hepatitis B, her-
pes zoster, HPV, meningococcal disease, and
pneumococcal disease are also responsible for
several delayed and chronic complications,
which were included in our analysis. For hepati-
tis B, the outcomes included acute infection,
chronic infection, cirrhosis, and liver cancer.
For herpes zoster (shingles), the outcomes in-
cluded herpes zoster without complications,
with post-herpetic neuralgia, and with other
complications. For HPV, the outcomes included
genital warts, cervical cancer, vaginal cancer,
vulvar cancer, anal cancer, and carcinoma in situ
of the cervix. Our HPV analysis examined the
impact of vaccination with Gardasil instead of
the more recently licensed Gardasil 9 because
of the limited evidence in the literature about
Gardasil 9. Our analysis did not include the costs
of preventive measures such as HPV screening.
For meningococcal and pneumococcal patho-
gens, the outcomes included meningitis, pneu-
monia, and sepsis.
For pneumococcal disease, a novel methodol-
ogy was devised to estimate 2015 cases that used
parameters described in the published literature
for all-cause pneumonia hospitalizations and
subsequent changes in disease burden after
the 7-valent and 13-valent pneumococcal conju-
gate vaccines (PCV7 andPCV13)were introduced
into childhood immunization schedules.6,8–10
This methodology first back-calculated pre-
PCV7 pneumococcal hospitalized incidence
and then applied the fraction of disease pre-
vented by PCV7 and PCV13 to assess the remain-
ing disease by incorporating serotype distribu-
tion, serotype replacement, nonhospitalized
pneumonia, indirect effects, and differential dis-
ease burden by age and risk group.11 The ratio of
total pneumococcal pneumonia to inpatient
pneumococcal pneumonia was applied to esti-
mate the incidence of total (inpatient and outpa-
tient) pneumococcal pneumonia. Similarly, the
ratio of hospitalized pneumonia to hospitalized
meningitis and sepsis cases was used to estimate
hospitalized pneumococcal meningitis and sep-
sis cases.6
Epidemiological Considerations And Ex-
pert Review Model development for the analy-
sis involved a series of interviews conductedwith
epidemiological experts regarding fourteen
pathogens related to each of the ten vaccines
recommended by the CDC. Twelve experts re-
viewedmodel assumptions to refine vaccine pre-
ventable disease–specific cost-of-illness models
and appropriately calibrate the epidemiological
parameters. Epidemiological considerations
and limitations that were viewed as important
to acknowledge and address were discussed and
incorporated. The main topics in each interview
included whether the decision tree adequately
reflected the path for potential adult vaccine-pre-
ventable infections; whether parameter esti-
mates were a reasonable reflection of adult vac-
cine-preventable disease epidemiology; and
what is a reasonable plausibility range for each
epidemiological parameter where ranges are not
available from the literature.
Costing Methodology
▸ COST-OF-ILLNESS MODEL: Two methods
were applied to estimate the overall economic
burden due to vaccine-preventable diseases in
US adults. First, we used a cost-of-illness model-
ing approach to estimate direct costs and pro-
ductivity losses due to vaccine-preventable dis-
eases.12,13 Thismethod calculatedamonetary cost
per patient and multiplied it by the number of
cases to obtain an aggregate cost of illness. This
analysis measured inpatient and outpatient
treatment costs, outpatient medication costs,
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epidemiological investigation costs for measles
outbreaks,14 and productivity losses in the form
of lost wages as a result of days of work missed
seeking treatment (for both inpatient and out-
patient care).We tooka conservative approachby
including only productivity lost to care seeking
and not wages lost because of disability or early
loss of life. This approach is supported by the
majority of burdenoccurring inadults older than
age sixty-five, who are predominantly no longer
participating in the workforce.
This study used nationwide databases and
International Classification of Diseases, Ninth Re-
vision (ICD-9), codes to assess the economic bur-
den of vaccine-preventable diseases among US
adults ages nineteen and older. Data were pri-
marily obtained from the following sources,with
someadditional cost information extracted from
literature review: the Nationwide Inpatient Sam-
ple (NIS) database from the Healthcare Cost and
Utilization Project (HCUP), the largest publicly
available all-payer inpatient care database in the
United States, including total charges;15 and the
Medical Expenditure Panel Survey (MEPS), a
national large-scale survey of families and indi-
viduals, their medical providers (doctors, hospi-
tals, pharmacies), and employers across the
United States, with data on specific health ser-
vices, including costs and source of payment.16
TheNISdatabasehousesdata for roughly eight
million hospital stays annually from approxi-
mately 1,000 hospitals sampled to approximate
a 20 percent stratified sample of US community
hospitals. The NIS is drawn from states partici-
pating in HCUP, which included 97 percent of
the US population as of 2011.We relied on 2010
and 2011 data for inpatient cost (including med-
ications) and length-of-stay data for hospitalized
adults.
The MEPS sampling frame is drawn from
respondents to the National Health Interview
Survey conducted by the National Center for
Health Statistics. MEPS collects data from an
overlapping panel design of a sample of house-
holds that are representative of the civilian
noninstitutionalized population. We used this
database to find outpatient costs, outpatient vis-
its per person, and prescription drug costs,
which we included in the model to calculate pre-
ventable costs from susceptible populations for
each pathogen. Given the smaller sample size of
approximately 30,000–35,000 people per year,
we averaged ten years of data (2001–10) from
this data source. Where there were gaps in epi-
demiological and cost parameters, we relied on
published literature.
▸ FULL INCOME MODEL:Wealso used a second
method, a full income model, to supplement the
results derived from the cost-of-illness method.
This method seeks to estimate the impact of
health indicators on economic welfare, using
estimates of mortality and a value-of-statistical-
life approach.17–24 In addition to capturing the
monetary value of market and nonmarket pro-
duction, thismethod also encompasses the value
of lives lost, interpreted as social welfare forgone
because of early death. This method uses re-
vealed preference studies to estimate how much
people already pay to prevent small life-threat-
ening risks in labor, housing, or product mar-
kets. For example, census data are used tomodel
wages as a function of death risk across a large
population.22 In addition, statedpreferencestud-
ies survey the population to elicit the amount an
individual is willing to pay to avoid certain risks
to life.17 Aggregating these individual values to a
societal level reflects a societal willingness to pay
for a specified mortality risk reduction.
The full income model was developed using
the following methodology. First, we applied
the standard rules used by the Congressional
Budget Office and the most recent literature
from the Environmental Protection Agency
(EPA), the Food and Drug Administration
(FDA), and the National Highway Traffic Safety
Administration (NHTSA) to determine a bench-
mark value and range for mortality risk reduc-
tion.25 These valueswere converted into2011dol-
larsusing theConsumerPrice Index.Thevalueof
mortality risk reduction was then multiplied by
thenumber of deaths attributable to vaccine-pre-
ventable diseases to obtain the total economic
value of immunization. Values were not calculat-
ed for diphtheria, HPV-induced genital warts,
HPV-induced carcinoma in situ of the cervix,
measles, mumps, and rubella, as it was assumed
that these vaccine-preventable diseases do not
result in death among adults. The full income
and cost-of-illness model results are expected
to diverge because the full income model in-
cludes the nonmarket value of living longer in
better health.
Our study highlights
the need for US adults
to better appreciate
the value of vaccines
to prevent economic
burden.
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Literature Review Validation A literature
review was conducted to collect unit costs and
productivity loss parameters for vaccine-pre-
ventable diseases to compare and validatemodel
inputs. Studies containing cost data in the Unit-
ed States for adult age groups were searched
across four databases: PubMed, Scopus, Econ-
Lit, and Embase.
The search strategy used a combination of the
National Library of Medicine’s Medical Subject
Headings (MeSH) controlled vocabulary terms
and free-text terms for costs, vaccines, and vac-
cine-preventable diseases. We used key search
terms related to the vaccines of interest and eco-
nomic analyses. Articles included in the review
were limited to those providing cost data for US
adults since 1993. Articles that pertained solely
to children or adolescents, focused on other
countries, did not look at costs, were published
prior to 1993, were not human studies, or con-
tained a non-English abstract were excluded. Ad-
ditional focus was given to articles reporting on
cases of rare conditions among US adults, such
asmeasles,mumps, rubella, diphtheria, tetanus,
and pertussis. Publications were included in our
search based on inclusion and exclusion criteria
from reading the title, abstract, and full text. The
full search strategy is detailed in Appendix D.7
Sensitivity Analysis Sensitivity analysis was
carried out through computer simulations to
present uncertainty ranges around key cost-of-
illness point estimates, including immunization
coverage, vaccine efficacy, incidence rates, and
unit costs. For each parameter, random draws
were taken from specified distributions 10,000
times. Noncost values were given a beta-PERT
distribution, while cost values incorporated a
gamma distribution to approximate the right
skew of observed costing data.26 This analysis
was implemented using the latest version of
the Palisade @RISK software to generate uncer-
tainty ranges for cost-of-illness results.
Limitations Our study had a number of key
limitations of note. The first was regarding data
abstracted from MEPS and the NIS. While the
MEPS database is nationally representative of
the entire US population, only a limited number
of cases were recorded for some adult vaccine-
preventable diseases. In addition, the NIS data-
base provides the largest publicly available inpa-
tient care data in the United States, but there
might be pockets of inpatient services not cap-
tured by this database. We also made assump-
tions using published literature and summary
data when vaccine preventable disease–specific
data were not available from the NIS or MEPS.
Second, limited sample sizes of cases for cer-
tain vaccine-preventable diseases included in
our study might limit the statistical power of
our results. This was a greater limitation for rare
adult conditions, such as measles, mumps, ru-
bella, diphtheria, tetanus, andpertussis. In cases
such as measles, mumps, or pertussis, the limit-
ed adult cases often occur in areas of low vaccine
uptake, which aremore likely in some geograph-
ic pockets and communities of certain income
levels. In addition, the small sample of diphthe-
ria cases (five in the past decade) challenges the
generalizability of diphtheria results.
In addition, there might be challenges with
classification of costs as a result of difficulties
in comprehensively identifying ICD9 codes and
linking cases by variouspathogens fromboth the
NIS andMEPSdata sets. Furthermore, theMEPS
data set was not accessible at the fully specified
ICD9 code level, and therefore it was assumed
that costs for three-digit summary codes were
relevant to vaccine-preventable disease subcon-
ditions.
Study Results
Through the literature review, our initial search
resulted in 25,660 articles across four databases:
5,953 in PubMed; 32 in Scopus; 91 in EconLit;
and 19,584 in Embase. After we reviewed titles
and abstracts, 500 of these articles were consid-
ered potentially relevant. Of these, 322 articles
were excluded through full-text screening as a
result of our exclusion criteria, including dupli-
cate article andarticles thatdidnot includecosts,
did not pertain to theUnited States, or pertained
solely to children or adolescents. A total of 178
articles were selected for inclusion in the final
review, some of which were used as inputs in the
cost-of-illness model.
Unit Costs The inpatient care unit costs ab-
stracted from median values of the NIS ranged
from $5,770 for a hospitalized case of influenza
to $15,600 for a hospitalized case of invasive
meningococcal disease. Abstracted from MEPS
as well as the supplementary literature, the out-
patient care unit costs ranged between $108 and
$457, while medication unit costs ranged from
$0 for diseases that do not have curative drug
treatment (as opposed to drugs prescribed to
treat symptoms) up to $605 for drugs used to
treat tetanus. The inpatient productivity loss per
person ranged from $122 for a case of mumps to
$580 for a case of tetanus, highlighting the se-
verity of tetanus among adultswith longhospital
stays. The outpatient productivity loss per per-
son ranged from $29 for diseases with only a
single outpatient visit per case to $154 for
HPV-related cancers, which involve more fol-
low-up visits. Exhibit 1 presents the average unit
costs used in the cost-of-illness model for each
cost component by pathogen.
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For most vaccine-preventable diseases, adults
ages sixty-five and older experienced the highest
unit costs, derived by dividing the total costs by
cases in Appendix E.7 Adults ages 19–49 had
higher unit costs for hepatitis A, cirrhosis, me-
ningococcal pneumonia, vaginal cancer, andvul-
var cancer. Adults ages 50–64 had higher unit
costs for liver cancer, mumps, meningococce-
mia, pneumococcal septicemia, and pneumococ-
cal pneumonia.
Economic Burden
▸ COST-OF-ILLNESS MODEL: The total current
economic burdenwas estimated at approximate-
ly $9 billion (plausibility range: $4.7–$15.2 bil-
lion) in 2015 from vaccine-preventable diseases
relevant to ten vaccines recommended for US
adults (Exhibit 2). The majority (95 percent)
of this estimated burden was for direct costs,
with $5.9 billion (plausibility range: $2.2–
$11.6 billion) for inpatient treatment costs and
$2.4 billion (plausibility range: $1.0–$4.8 bil-
lion) for outpatient treatment costs. The remain-
ing 5 percent represents productivity losses as a
result of wages lost during the course of treat-
ment. Epidemiological investigations for mea-
sles outbreaks were estimated to cost $139,000
per year on average. Uncertainty ranges are pre-
sented in Appendix F.7
Sixty-five percent of the estimated annual eco-
nomic burden, equivalent to $5.8 billion (plau-
sibility range: $2.0–$11.6 billion), resulted from
influenza alone—a vaccine-preventable disease
that causes substantial numbers of hospitaliza-
tions and morbidity each year (Exhibit 3). An
additional 21 percent ($1.9 billion) resulted from
pneumococcal disease, and 9 percent ($782 mil-
lion) was contributed by herpes zoster. The last
6 percent of the total economic burden was dis-
tributed among the remaining eleven patho-
gens, some ofwhich are exceedingly rare in their
disease presentation among US adults.
The economic burden attributable to vaccine-
preventable diseases was also found to vary by
age. For people ages 19–49, influenza repre-
sented the greatest remaining vaccine-prevent-
able economic burden at 85 percent of the annu-
al total, followed by HPV at 12 percent. For
people ages50–64, influenza contributed67per-
cent of the economic burden, and herpes zoster
contributed 20 percent. For adults ages 65 and
older, influenza (55 percent) and pneumococcal
disease (35 percent) constituted the greatest
proportion of remaining economic burden. An-
nual cases and economic burden by pathogen
and age group are presented in Appendix E.7
Results show that 76 percent of the current
cases (14.1 million) were attributable to unvacci-
nated individuals. The percentage of cases attrib-
Exhibit 1
Unit costs per case of vaccine-preventable disease by cost component and by pathogen used in cost-of-illness model, 2015
Direct costs Productivity losses
Pathogen
Inpatient
unit cost
Outpatient
unit cost
Medication
unit cost
Inpatient
productivity loss
per person
Outpatient
productivity loss
per person
Hepatitis A $ 6,590 $201 $ 0 $178 $ 58
Hepatitis B 8,940 457 223 193 23
Herpes zoster 6,160 248 40 295 54
Influenza 5,770 258 24 132 24
Measlesa 8,690 108 0 212 29
Mumps 9,200 108 0 122 29
Rubella 6,030 108 0 176 29
Tetanus 14,400 108 605 580 29
Diphtheria 8,490 108 50 244 29
Pertussis 7,730 108 100 200 29
Varicella 7,540 112 47 273 29
Meningococcal disease 15,600 108 50 406 58
Pneumococcal disease 15,200 108 50 348 48
HPV 11,600 236 77 195 154
Source NIS MEPS and lit. MEPS and lit. NIS and DOL MEPS and DOL
SOURCE Authors’ analysis. NOTES HPV is human papillomavirus. NIS is Nationwide Inpatient Sample. MEPS is Medical Expenditure
Panel Survey. DOL is Department of Labor. aThe measles pathogen also included a cost component for epidemiological
investigations valued at $1,470 (see Note 14 in text).
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utable to unvaccinated individuals also de-
creases with age, with adults ages 19–9, having
85 percent of vaccine-preventable diseases
among theunvaccinated, compared to81percent
for adults ages 50–64 and 56 percent for adults
ages 65 and older. Eighty percent of the estimat-
ed remaining annual economic burden, equiva-
lent to $7.1 billion (plausibility range: $3.8–
$11.9 billion), resulted from these individuals,
who received no direct protection from vaccina-
tion. The percentage of economic burden attrib-
utable to unvaccinated individuals ranged from
65 percent for varicella to more than 99 percent
for pertussis and hepatitis A.
▸ FULL INCOME MODEL: The current-dollar
value of statistical life calculated from each
sourcewas$5.9billion fromtheFDA;$6.3billion
from the NHTSA; and $8.3 billion from the EPA.
The full income value of death as a result of
vaccine-preventable diseases is estimated to be
$176 billion annually (plausibility range:
$166 billion–$231 billion). Two-thirds (66 per-
cent) of the full income value each year is attrib-
utable to hepatitis B alone (plausibility range:
$110 billion–$152 billion), including acute and
chronic infection, cirrhosis/chronic liver dis-
ease, and liver cancer. An additional 19 percent
is attributable toHPV (plausibility range: $31 bil-
lion–$44 billion), and 5 percent to influenza
(plausibility range: $8 billion–$11 billion). The
remaining pathogens are all less than 5 percent
of the overall full income value.
Discussion
Our estimation of the economic burden of vac-
cine-preventable diseases in adults highlights
the importance of increasing adult vaccine up-
take in the United States.We found that unvacci-
nated cases contributed a significant portion of
total costs attributable to vaccine-preventable
diseases. Based on current vaccination uptake
rates, vaccine-preventable diseases annually cost
individuals and society $9 billion (plausibility
range: $4.7–$15.2 billion) through direct costs
and productivity losses, $7.1 billion (plausibility
range: $3.8–$11.9 billion) of which occurs
among the unvaccinated. This indicates the po-
tential impact that increased adult immuniza-
tion rates might have on decreasing the annual
economic burden, particularly among younger
adults. It should be noted that this study exam-
ined a static annual estimate of the unvaccinated
cohort, and therefore not all cases in this group
arenecessarily preventable by increased vaccina-
tion because of less than 100 percent vaccine
efficacy as well as a target population that has
agedout of the recommended age range for some
of the vaccines. Furthermore, our analysis esti-
mated current vaccine-preventable disease bur-
Exhibit 2
Total annual cases and economic burden of vaccine-preventable disease, by pathogen, 2015
Direct costs Productivity loss
Pathogen Cases Inpatient cost
Outpatient
cost
Medication
cost Inpatient Outpatient Total costs
Hepatitis A 1,930 $ 2,160,000 $ 682,000 $ 0 $ 58,200 $ 98,500 $ 3,000,000
Hepatitis B 43,400 141,000,000 24,300,000 4,800,000 2,410,000 985,000 173,000,000
Herpes zoster 1,100,000 197,000,000 477,000,000 41,600,000 10,600,000 55,700,000 782,000,000
Influenza 16,600,000 3,770,000,000 1,580,000,000 175,000,000 86,100,000 178,000,000 5,790,000,000
Measlesa 95 79,100 10,300 0 1,930 2,750 233,000
Mumps 394 72,400 42,600 0 964 11,400 127,000
Rubella 1 3,330 60 0 97 16 3,500
Tetanus 26 134,000 1,040 5,820 5,410 279 147,000
Diphtheriab <1 3,900 5 23 112 13 4,100
Pertussis 4,450 1,580,000 482,000 445,000 40,900 129,000 2,680,000
Varicella 9,220 528,000 985,000 412,000 19,100 254,000 2,200,000
Meningococcal disease 303 4,750,000 65,600 16,900 102,000 17,600 5,000,000
Pneumococcal disease 283,000 1,760,000,000 27,400,000 14,000,000 49,000,000 8,220,000 1,860,000,000
HPVc 447,000 29,200,000 244,000,000 19,500,000 472,000 40,000,000 333,000,000
Total 18,500,000 5,910,000,000 2,360,000,000 256,000,000 149,000,000 283,000,000 8,950,000,000
SOURCE Authors’ analysis. NOTE All estimates are rounded to three significant figures. aMeasles total costs include $139,000 for epidemiological investigation cost.
bBecause of the rare incidence of diphtheria among adults in the United States, no more than a single case is expected; therefore, the economic burden would not
exceed the per person costs. cOnly the vaccine-preventable conditions of human papillomavirus (HPV) are included; oropharyngeal cancer, penile cancer, and
recurrent respiratory papillomatosis are excluded.
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den instead of disease burden prevented as a
result of vaccination or implementation of spe-
cific vaccine recommendations.
This study presents a more comprehensive
analysis of the economic burden of vaccine-
preventable diseases among US adults than pre-
viously conducted. The methodology of this
review not only estimated the direct costs and
productivity losses associated with vaccine-pre-
ventable diseases with a cost-of-illness approach
but also included the value of averting death
attributable to a vaccine-preventable cause using
the full incomemodel; both approaches are com-
monly used to estimate economic burden in the
United States.5,19,21,24
Several other studies have sought to estimate
the economic costs of various vaccine-prevent-
able illnesses in theUnitedStates. For example, a
previous CDC analysis estimated that annual in-
fluenza epidemics are estimated to cost between
$1.6 billion and $25.2 billion in direct medical
expenses amongUS adults.3 Our study estimated
direct medical costs within this range at $5.5 bil-
lion for seasonal influenza. In a different study,
US adults ages 18–49 accounted for 10 percent of
the total economic burden from influenza,27
whereas ouranalysis estimated that youngadults
accounted for 31 percent. A recent analysis by
John McLaughlin and colleagues looked at four
of the vaccine-preventable diseases considered
in the study (influenza, pneumococcal disease,
herpes zoster, and pertussis) and estimated an-
nual costs of $26.5 billion for US adults older
than age fifty, compared to our conservative es-
timate of $6.9 billion for the same diseases and
age group.28 The higher pertussis incidence,
higher base-case estimates from different sourc-
es, higher overall cost per case used, and addi-
tional indirect costs measured led to the higher
costs observed by McLaughlin and colleagues.
While we found some variation between our
estimates and those cited in the literature, this
could be attributable to differences inmethodol-
ogy. As seen in Exhibit 1, among some uncom-
plicated acute cases such as hepatitis A and in-
fluenza, we saw similar direct costs as measured
by inpatient cost per person. Overall, we saw
larger outpatient care costs in the literature,
which indicates that outpatient care unit costs
fromMEPSmight be an underestimate. Because
we included costs of only medication used for
curative treatment, not treatment of symptoms,
we did not include medication costs for diseases
such as hepatitis A, for which such costs are
sometimes calculated in the literature. We also
saw greater variation in uncomplicated acute
cases such asmeasles, a vaccine-preventable dis-
ease that we estimated would have an inpatient
cost of $8,690 according to adult-specific NIS
data, whereas other literature estimated a cost
of $2,660 across all age groups.29,30 A full com-
parison of inpatient care unit costs can be found
in Exhibit 4.
There was also some variation in costs of cases
with complications, which was not surprising
considering the increased complexity and varia-
tion in the methodology used to calculate costs
among these cases, particularly within disease-
specific studies. Similarities and variations were
additionally observedamonguncomplicatedver-
sions of these cases. For example, we estimated
that uncomplicated herpes zoster had inpatient
costs per person of $5,280—a slightly lower fig-
ure compared to the $7,680 in the literature, but
within the estimated range of $4,440–$8,890.31
Because of the many pathogens included in
this analysis, we excluded treatment costs for
sequelae (negative after-effects) for vaccine-
preventable pneumococcal and meningococcal
diseases from the total economic burden, as this
information was not available for other patho-
gens. However, we examined this cost compo-
nent separately. The lifetime sequelae treatment
cost for meningococcal meningitis and sepsis as
Exhibit 3
Annual economic burden of vaccine-preventable diseases, by pathogen, 2015
SOURCE Authors’ analysis. NOTES All dollar amounts are for all US adults relevant to each vaccine-
preventable disease (which target different age groups). The breakdown of results by age is pre-
sented in the online Appendix (see Note 7 in text). HPV is human papillomavirus. aIncludes economic
burden attributable to diphtheria, hepatitis A, measles, meningococcal disease, mumps, pertussis,
rubella, tetanus, and varicella.
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well as pneumococcalmeningitiswere estimated
at $273,000 per case.6 For meningococcal dis-
ease, the economic burden to treat sequelae such
as deafness and limb loss resulting from menin-
gitis or sepsis are estimated to be $11.5 million
over adults’ lifetimes. Forpneumococcal disease,
the economic burden to treat sequelae resulting
from pneumococcal meningitis are estimated to
be approximately $57.3 million over adults’
lifetimes.
Theapproach to estimatingproductivity losses
in this study could also be considered very con-
servative, as not all productivity losses attribut-
able to disability and death were included. This
study focusedonlyonproductivity loss as a result
of care seeking instead of impact on income, as
significant burden was observed in adults age
sixty-five or older. Productivity losses related
to care seekingmight underestimate the full eco-
nomic burden becausewe did not estimate work-
related productivity loss for younger ages for
additional missed work for convalescence and
recovery outside of direct inpatient and out-
patient care. We did not specifically model pa-
rameter differences for immunocompromised
populations, which might have different risks
for diseases as well as higher treatment costs.
This study examined a static cross-section of
the adult population instead of taking a co-
hort-based approach.
Conclusion
The results of this study demonstrate the need
for improved uptake of vaccines among adults
based on a robust analysis of the societal and
individual costs stemming fromvaccine-prevent-
able diseases among vaccinated and unvaccinat-
edpopulations. Estimating theeconomicburden
of vaccine-preventable diseases among adults is
a first step toward understanding the benefits of
increasing adult vaccine uptake in the United
States. It highlights the need for US adults to
better appreciate the value of vaccines to prevent
economic burden. By highlighting the tremen-
dous financial burden that unvaccinated individ-
uals place on the economyand thehealth system,
we hope that our estimates will spur creative
policy solutions to reduce the negative externali-
ty or spillover effect, while preserving the auton-
omy of patients to make more informed
choices. ▪
Exhibit 4
Unit costs per case of vaccine-preventable disease with inpatient care compared to results from a literature review, 2015
Pathogen Costs from NISa Costs from the literatureb Literature source
Hepatitis A $3,970–$9,570 $2,890–$7,220 Berge et al., 2000
Hepatitis B $5,220–$16,100 $8,600 Lee et al., 2004
Herpes zoster $3,690–$10,400 $4,460–$8,890 Hornberger and Robertus, 2006 (Note 31 in text)
Influenza $3,650–$9,660 $4,930–$5,680 Lin et al., 2013
Measles $5,570–$14,200 $2,660 Miller et al., 1998 (Note 29 in text); Shim et al., 2012 (Note 30 in text)
Mumps $6,750–$13,400 $2,660 Miller et al., 1998 (Note 29 in text); Shim et al., 2012 (Note 30 in text)
Rubella $3,940–$9,730 $2,660 Miller et al., 1998 (Note 29 in text); Shim et al., 2012 (Note 30 in text)
Tetanus $9,110–$48,300 $31,200 Balestra and Littenberg, 1993
Diphtheria $7,580–$9,540 Not available
Pertussis $3,600–$12,600 $860–$34,500 O’Brien and Caro, 2005
Varicella $4,830–$14,000 $6,100 Smith and Roberts, 1998
Meningococcal disease $9,070–$34,800 $14,700–$32,400 Scott et al., 2002
Pneumococcal disease $8,880–$27,000 $25,200–$30,100 Smith et al., 2010
HPV $7,580–$18,700 $27,200–$55,700c Chesson et al., 2012
SOURCES Authors’ analysis and literature review. Complete citations, except where indicated, are in online Appendix G (see Note 7 in text). NOTES Costs were converted
into current-year dollars. NIS is Nationwide Inpatient Sample. HPV is human papillomavirus. aRange from the NIS includes twenty-fifth and seventy-fifth percentiles.
bIncludes uncertainty ranges from the literature where available. cThis is an average direct medical cost for cervical, anal, vaginal, and vulvar cancers, including
screening and treatment costs beyond inpatient care, such as recurrence and terminal care. The robustness of these data differs by cancer.
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